TABLE E1.
Baseline Characteristics of Study Population (n = 155)
| Characteristic | No. (%) |
|---|---|
| Demographics | |
| Age (yrs), median (range) | 11.4 (6.1-18.4) |
| Male gender | 96 (62) |
| Race | |
| American Indian/Alaska Native | 1 (1) |
| Asian | 0 (0) |
| Black/African American | 63 (41) |
| Mixed race | 26 (17) |
| Native Hawaiian/Other Pacific Islander | 1 (1) |
| White | 64 (41) |
| Hispanic ethnicity | 22 (14) |
| Annual household income <$25,000 | 51 (37) |
| Clinical characteristics | |
| BMI category | |
| Underweight (<5th percentile) | 2 (1) |
| Normal weight (5th - <85th percentile) | 66 (43) |
| Overweight (85th - <95th percentile) | 33 (21) |
| Obese (≥95th percentile) | 54 (35) |
| ACT score, mean (SD)1 | 18.2 (4.5) |
| ≥ 1 asthma exacerbation in past year | 101 (66) |
| ICS use over prior 12 months | 147 (95) |
| Severe Asthma* | 89 (57) |
| Blood markers of atopy/inflammation | |
| ≥ 1 positive specific IgE3 | 138 (91) |
| Serum IgE conc (kU/L), mean (SD)4 | 868 (1328) |
| Blood eosinophil count (cells/uL), mean (SD)5 | 395 (296) |
| FENO (ppb), mean (SD)2 | 35.7 (37.8) |
| Pulmonary function testing6 | |
| FEV1 % predicted, pre-bronchodilator, mean (SD) | 90.5 (14.1) |
| FVC % predicted, pre-bronchodilator, mean (SD) | 103.5 (13.0) |
| FEV1/FVC, pre-bronchodilator, mean (SD) | 76.7 (8.8) |
| FEV1 % predicted max. absolute reversibility, mean (SD) | 12.3 (12.5) |
1
n = 155 ACT scores
2
n = 152 FENO samples
3
n = 152 specific IgE samples
4
n = 146 IgE samples
5
n = 155 CBC samples
6
n = 155 PFTs
*
The classification of severe asthma was determined using criteria from the American Thoracic Society/European Thoracic Society guidelines.
Abbreviations: BMI = body mass index; ACT = Asthma Control Test; ICS = inhaled corticosteroid; IgE = immunoglobulin E; FENO = fraction of exhaled nitric oxide; ppb = parts per billion; SD = standard deviation; FVC = forced vital capacity; FEV1 = forced expiratory volume in 1 second